Skip Navigation
Johns Hopkins Bloomberg School of Public HealthCAAT

Toxicometabolomics Information Day

Wednesday, November 13, 2013
Johns Hopkins Bloomberg School of Public Health
615 N. Wolfe Street, Feinstone Hall #E2030
Baltimore MD 21205

A mechanistic toxicology has evolved over the last decades, which is effectively relying to large extent on methodologies which substitute or complement traditional animal tests. The biotechnology and informatics revolution of the last decades has made such technologies broadly available and useful. Metabolomics, as an emerging field of ‘omics’ research, primarily concerns comparative analysis of the metabolites present in any biological system or any specific physiological state. It aims to characterize and identify the metabolites – the end products of cellular metabolism-, providing information on toxicological modes of action; revealing pathways of toxicity and facilitating the identification of biomarkers.

This conference brings together scientists from academia and industry to present the current status of this technology and its applicability in toxicology.

Program

8:00-8:50
Continental Breakfast

8:50-9:00
Introduction

9:00-9:35
Metabolomics in Cell Assay Studies Status and Prospects and Adverse Outcome Approaches
Thomas Hartung, Johns Hopkins Bloomberg School of Public Health

9:35-10:10
Metabolomics Platform at CAAT
Liang Zhao, Johns Hopkins Bloomberg School of Public Health

10:10-10:45
Metabolomics as a Tool to Assess Drug Safety
Don Robertson, Bristol-Myers Squibb Co, Applied and Investigative Metabolomics

10:45-11:05
Break

11:05-11:40
Metabolomics as a Unique Biochemical Approach for Understanding Disease Pathogenesis
Gary Siuzdak, The Scripps Research Institute, Center for Metabolomics and Mass Spectrometry

11:40-12:15
Inclusion of a Metabolomics Approach in the Assessment of Genotoxicity of Toxicants in vitro and in vivo
Al Fornace, Georgetown University, Lombardi Comprehensive Cancer Center

12:15-1:15
Lunch

1:15-1:50
Quality Aspects of Metabolomics Studies
Mounir Bouhifd, Johns Hopkins Bloomberg School of Public Health

1:50-2:25
Using the Serum Exposome to Discover Causes of Disease
Anthony Macherone, Agilent Technologies, Inc. and Visiting Scientist, Johns Hopkins School of Medicine

2:25-3:00
Discovering Biomarkers of Human Disease and Development Using Stem Cells and Metabolomics
Paul West, Stemina Biomarker Discovery, Inc.

3:00-3:35
Application of Metabolomics in Preclinical and Industrial Toxicology – MetaMapTox
Hennicke Kamp, BASF SE, Experimental Toxicology and Ecology

3:35-3:55
Summary of the Day

3:55-4:00
Closing Remarks
Thomas Hartung, Johns Hopkins Bloomberg School of Public Health

For more information email Marilyn Principe.